We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Slim bet

6 December 2007 By Robert Cyran

The drug company appeared takeover bait last summer. But government oversight and a patent dispute gave the company a window of safety. This may have closed, but Bristol s restructuring and a rising valuation may be enough to ensure independence.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)